Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A. Hadaschik; Julie N. Graff; David Olmos; Paul N. Mainwaring; Ji Youl Lee; Hiroji Uemura; Peter De Porre; Andressa A. Smith; Sabine D. Brookman-May; Susan Li; Ke Zhang; Brendan Rooney; Angela Lopez-Gitlitz; Eric J. Small

doi:10.1016/j.eururo.2020.08.011

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith
, Fred Saad
, Simon Chowdhury
, Stéphane Oudard
, Boris A. Hadaschik
, Julie N. Graff
, David Olmos
, Paul N. Mainwaring
, Ji Youl Lee
, Hiroji Uemura
, Peter De Porre
, Andressa A. Smith
, Sabine D. Brookman-May
, Susan Li
, Ke Zhang
, Brendan Rooney
, Angela Lopez-Gitlitz
, Eric J. Small

Department of Urology

MGH Cancer Center
Centre Hospitalier de L'Universite de Montreal
St Thomas' Hospital
Pôle de Biologie
University of Duisburg-Essen
Oregon Health and Science University
Centro Nacional de Investigaciones Oncológicas
Canossa Hospital
Yokohama City University
Johnson & Johnson
Ludwig Maximilian University of Munich
University of California at San Francisco

Research output: Contribution to journal › Article › peer-review

253 Scopus citations

Abstract

Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

Original language	English
Pages (from-to)	150-158
Number of pages	9
Journal	European Urology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2020.08.011
State	Published - Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Apalutamide
Nonmetastatic castration-resistant prostate cancer
Overall survival
Subsequent therapy
Time to cytotoxic chemotherapy

Access to Document

10.1016/j.eururo.2020.08.011

Cite this

Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., De Porre, P., Smith, A. A., Brookman-May, S. D., Li, S., Zhang, K., Rooney, B., Lopez-Gitlitz, A., & Small, E. J. (2021). Apalutamide and Overall Survival in Prostate Cancer. European Urology, 79(1), 150-158. https://doi.org/10.1016/j.eururo.2020.08.011

@article{d9bc2d38d9444b14b63981b40cfc4337,

title = "Apalutamide and Overall Survival in Prostate Cancer",

abstract = "Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.",

keywords = "Apalutamide, Nonmetastatic castration-resistant prostate cancer, Overall survival, Subsequent therapy, Time to cytotoxic chemotherapy",

author = "Smith, \{Matthew R.\} and Fred Saad and Simon Chowdhury and St{\'e}phane Oudard and Hadaschik, \{Boris A.\} and Graff, \{Julie N.\} and David Olmos and Mainwaring, \{Paul N.\} and Lee, \{Ji Youl\} and Hiroji Uemura and \{De Porre\}, Peter and Smith, \{Andressa A.\} and Brookman-May, \{Sabine D.\} and Susan Li and Ke Zhang and Brendan Rooney and Angela Lopez-Gitlitz and Small, \{Eric J.\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2021",

month = jan,

doi = "10.1016/j.eururo.2020.08.011",

language = "English",

volume = "79",

pages = "150--158",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Apalutamide and Overall Survival in Prostate Cancer

AU - Smith, Matthew R.

AU - Saad, Fred

AU - Chowdhury, Simon

AU - Oudard, Stéphane

AU - Hadaschik, Boris A.

AU - Graff, Julie N.

AU - Olmos, David

AU - Mainwaring, Paul N.

AU - Lee, Ji Youl

AU - Uemura, Hiroji

AU - De Porre, Peter

AU - Smith, Andressa A.

AU - Brookman-May, Sabine D.

AU - Li, Susan

AU - Zhang, Ke

AU - Rooney, Brendan

AU - Lopez-Gitlitz, Angela

AU - Small, Eric J.

PY - 2021/1

Y1 - 2021/1

N2 - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

AB - Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

KW - Apalutamide

KW - Nonmetastatic castration-resistant prostate cancer

KW - Overall survival

KW - Subsequent therapy

KW - Time to cytotoxic chemotherapy

UR - https://www.scopus.com/pages/publications/85090311385

U2 - 10.1016/j.eururo.2020.08.011

DO - 10.1016/j.eururo.2020.08.011

M3 - Article

C2 - 32907777

AN - SCOPUS:85090311385

SN - 0302-2838

VL - 79

SP - 150

EP - 158

JO - European Urology

JF - European Urology

IS - 1

ER -

Apalutamide and Overall Survival in Prostate Cancer

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this